期刊文献+

HPLC法测定盐酸非索非那定缓释片中盐酸非索非那定及有关物质含量

Development and validation of an HPLC method for the determination of fexofenadine hydrochloride and its related substances in sustained release tablets
下载PDF
导出
摘要 目的建立HPLC法测定盐酸非索非那定缓释片中盐酸非索非那定及有关物质的含量。方法采用Hypersil CN色谱柱(4.6 mm×200 mm,5μm);以乙腈–0.005mol·L-1磷酸二氢铵(体积比为53:47,用磷酸调节pH为3.5)为流动相,流速1.0 mL·min-1,检测波长210 nm,柱温为40℃。结果盐酸非索非那定在20~120 mg·L-1内线性关系良好,回归方程A=1.623×104ρ–5.830×103,r=0.999 9,最低检测限为3.0 mg·L-1。本方法的重现性和精密度良好,日内日间的RSD分别【2.0%、【2.5%。80.0、120.0、140.0 g·L-1低、中、高3种质量浓度下,方法的平均回收率分别为99.5%、99.8%、99.8%,RSD为0.27%、0.16%、0.32%。有关物质可很好分离。结论方法可用于盐酸非索非那定缓释片的质量控制。 Objective To develop an HPLC method for the determination of fexofenadine hydrochloride and its related substances in sustained release tablets. Method Fexofenadine hydrochloride and its related substances were separated using a mobile phase consisting of acetonitrile-buffer(0.005 mol·L-1monobasic ammonium phosphate, adjust pH to 3.5 by phosphoric acid)(V:V = 53:47) at a flow rate of 1.0mL·min-1on a Hypersil CN column(4.6 mm×200 mm, 5 μm) and detected at UV wavelength 210 nm. Result There was a good linear relationship within the range of 20–120 mg·L-1(r=0.999 9), The limit of detection(LOD)for the method was 3.0 μg·mL-1(S/N=3). The reproducibility and precision of the method are good. The intra-day RSD and inter-day RSD were less than 2.5% and 2.0%, respectively. The average method recoveries were 99.5%, 99.8% and 99.8% for the low(80.0 mg·L-1), middle(120.0 mg·L-1) and high(140.0 mg·L-1)concentrations of check samples, respectively. The related substance can be separated as wel1. Conclusion The method is simple, rapid, accurate and is suitable for the determination of content and related subsances of fexofenadine hydrochloride in sustained release tablets.
出处 《中国药剂学杂志(网络版)》 2005年第6期329-334,共6页 Chinese Journal of Pharmaceutics:Online Edition
关键词 药剂学 含量测定 高效液相色谱法 盐酸非索非那定缓释片 有关物质 pharmaceutics content determination HPLC fexofenadine hydrochloride sustained release tablets related substance
  • 相关文献

参考文献9

  • 1高立军,王维贤.高效液相色谱法测定盐酸托烷司琼片的含量[J].科学技术与工程,2012,20(28):7347-7349. 被引量:2
  • 2吴爱琴,林曼,吴昭怡,张志豪,李怡,兰缨.HPLC法测定盐酸非索非那定片的有关物质[J].广东药学院学报,2004,20(5):478-479. 被引量:7
  • 3杨森,张学军.抗组胺药物应用进展[J].中国新药与临床杂志,2002,21(3):177-180. 被引量:11
  • 4凌大奎.有关物质及其高效液相色谱测定法[J].中国药学杂志,2000,35(8):567-569. 被引量:41
  • 5Ute Hofmann,Monika Seiler,Siegfried Drescher,Martin F Fromm.Determination of fexofenadine in human plasma and urine by liquid chromatography–mass spectrometry[J]. Journal of Chromatography B . 2002 (2)
  • 6MaxineStoltz,ThangamArumugham,ChristinaLippert,DaleYu,VijayBhargava,MarkEller,ScottWeir.Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16 455A)[J]. Biopharm. Drug Dispos. . 1998 (7)
  • 7David I Bernstein,William F Schoenwetter,Robert A Nathan,William Storms,Robert Ahlbrandt,Jolene Mason.Efficacy and Safety of Fexofenadine Hydrochloride for Treatment of Seasonal Allergic Rhinitis[J]. Annals of Allergy, Asthma & Immunology . 1997 (5)
  • 8D. Tinkelman,C. Falliers,E. Bronsky,H. Kaiser,J. Mason.1009 Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis[J]. The Journal of Allergy and Clinical Immunology . 1996 (1)
  • 9Russell T,Stoltz M,Weir S.Pharmacokinetics and tolerance of single- and multiple-dose fexofenadme hydrochloride in healthy male volunteers. Clinical Pharmacology and Therapeutics . 1998

二级参考文献25

  • 1周海钧,王秀文.人用药品注册技术规范国际协调会(ICH)──安全性的技术要求[J].中国药学杂志,1996,31(12):762-764. 被引量:3
  • 2周海钧,中国药学杂志,1996年,31卷,10期,627页
  • 3.中国药典二部[M].,2005.717.
  • 4MARKHAM A, WAGSTAFF AJ. fexofenadine[J]. Drugs, 1998,55(2):269-274 .
  • 5NACLERIO RM. All allergic rhinitis[J]. N Engl J Med,1991,325(12):860-8 69.
  • 6PHILPOT EE. Safety of second generation antihistamines[J]. Allergy Ast hma Proc,2000,21(1):15-21.
  • 7MONAHAN BP, FERGUSON CL, KILLEAVY ES. Torsade pointers occurring in assoc iation with terfenadine use[J]. JAMA, 1990,264(21):2788-2790.
  • 8GUPTAA K, KATZ HI, SHEAR NH. Drug interactions with intraconazole, fluco nazole and terbinafine and their management[J]. J Am Acad Dermatol, 1999,412 P t 1:237-249.
  • 9SLATER JW, ZECHNICH AD, HARBY DG. Second-generation antihistamine: a comp arative review[J]. Drugs,1999,57(1):31-47.
  • 10LINDQUIST M, EDWARDS IR. Risk of non-sedating antihistamine[J]. Lancet ,1997,349(9061):1322.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部